Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals.
Sigma receptors are classified into sigma(1) and sigma(2) subtypes. These subtypes display a different tissue distribution and a distinct physiological and pharmacological profile in the central and peripheral nervous system. The characterization of these subtypes and the discovery of new specific sigma receptor ligands demonstrated that sigma receptors are novel targets for the therapeutic treatment of neuropsychiatric diseases (schizophrenia, depression, and cognition), brain ischemia, and cocaine addiction. Furthermore, imaging of sigma(1) receptors in the human brain using specific PET radioligands has started. In addition, the two sigma receptor subtypes are also expressed on tumor cells, where they could be of prognostic relevance. The ability of sigma(2) receptor agonists to inhibit tumor cell proliferation through mechanisms that might involve apoptosis, intracellular Ca(2+), and sphingolipids has promoted the development of sigma(2) receptor agonists as novel therapeutic drugs for treating cancer. Consequently, sigma(2) receptor ligands have been demonstrated to be potentially useful tumor imaging ligands. In this article, we focus on the sigma receptor ligands as therapeutic agents and as radiopharmaceuticals.
Hashimoto
Kenji
K
Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan.
Ishiwata
Kiichi
K
D000818:Animals; D014150:Antipsychotic Agents / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D008024:Ligands; D001523:Mental Disorders / Q000188:drug therapy / Q000378:metabolism; D019275:Radiopharmaceuticals / Q000378:metabolism / Q000627:therapeutic use*; D017480:Receptors, sigma / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000378:metabolism
D014150:Antipsychotic Agents; D008024:Ligands; D019275:Radiopharmaceuticals; D017480:Receptors, sigma